This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RAIN Rain Oncology (RAIN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsEarningsHeadlinesInsider TradesOwnershipTrendsBuy This Stock About Rain Oncology Stock (NASDAQ:RAIN) 30 days 90 days 365 days Advanced Chart Get Rain Oncology alerts:Sign Up Key Stats Today's Range$3.82▼$4.8050-Day Range$1.20▼$1.2452-Week Range$0.82▼$11.32Volume32,030 shsAverage Volume32,376 shsMarket Capitalization$23.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAs of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.Read More… Receive RAIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address RAIN Stock News Headlines'AI Can Detect Cancer, But Bengaluru Still Can’t Handle Rain?' Investor's Viral Rant Sparks DebateMay 21 at 10:39 PM | msn.comThousands brave rainy weather for Race For Hope to fund brain cancer researchMay 9, 2025 | msn.comThe “black glass” breakthrough behind AI’s next leapAI is advancing fast… But there’s one problem almost no one’s talking about. Power.May 24, 2025 | True Market Insiders (Ad)10-year-old cancer survivor rings bell, throws first pitch at Space Cowboys gameMay 3, 2025 | msn.comLead singer for popular U.K. rock band dies at 66May 1, 2025 | msn.comMike Peters Dies: The Alarm’s Frontman Was 66May 1, 2025 | msn.comToronto runners brave rain to raise roughly $23,000 for cancer fightMarch 15, 2025 | msn.com13-year-old rain cancer survivor calls out Democrats: ‘Stop being mean to Trump’March 8, 2025 | msn.comSee More Headlines RAIN Stock Analysis - Frequently Asked Questions How were Rain Oncology's earnings last quarter? Rain Oncology Inc. (NASDAQ:RAIN) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter. When did Rain Oncology IPO? Rain Oncology (RAIN) raised $126 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities served as the underwriters for the IPO. Who are Rain Oncology's major shareholders? Top institutional investors of Rain Oncology include Polar Asset Management Partners Inc. (0.52%) and Apollo Management Holdings L.P. (0.43%). Insiders that own company stock include Bvf Partners L P/Il, Boxer Capital, Llc, Franklin M Berger and Paul T Dacier. View institutional ownership trends. What other stocks do shareholders of Rain Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rain Oncology investors own include CRISPR Therapeutics (CRSP), Meta Platforms (META), UiPath (PATH), Recursion Pharmaceuticals (RXRX), Alibaba Group (BABA), NVIDIA (NVDA) and Company Calendar Last Earnings5/15/2025Today5/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:RAIN CIK1724979 Webwww.rainthera.com Phone510-953-5559FaxN/AEmployees63Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.10 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-9.51% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.57 per share Price / Cash Flow7.41 Book Value($0.69) per share Price / Book-6.12Miscellaneous Outstanding Shares5,540,000Free Float4,574,000Market Cap$23.38 million OptionableNo Data Beta-0.11 Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RAIN) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredThe “black glass” breakthrough behind AI’s next leapAI is advancing fast… But there’s one problem almost no one’s talking about. Power.True Market Insiders | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rain Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rain Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.